{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:53:19Z","timestamp":1780595599155,"version":"3.54.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s13555-025-01515-x","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T11:20:39Z","timestamp":1756984839000},"page":"3089-3108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Strategies for Optimal Use of Biological Therapies in Managing Psoriasis: Focus on Secukinumab"],"prefix":"10.1007","volume":"15","author":[{"given":"Anna","family":"Balato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Burlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-0839","authenticated-orcid":false,"given":"Anna","family":"Campanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Chiricozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Micali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Psoriasis Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Astrua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Bianchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Buligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Di Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Leporati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mugheddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Pagnanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Pietroleonardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Sacchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Trovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"1515_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180","volume":"8","author":"G Damiani","year":"2021","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med (Lausanne). 2021;8: 743180.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"1515_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","volume":"31","author":"IM Michalek","year":"2017","unstructured":"Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205\u201312.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1515_CR3","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.3390\/life12122026","volume":"12","author":"A Balato","year":"2022","unstructured":"Balato A, Zink A, Babino G, et al. The impact of psoriasis and atopic dermatitis on quality of life: a literature research on biomarkers. Life (Basel). 2022;12(12):2026. https:\/\/doi.org\/10.3390\/life12122026.","journal-title":"Life (Basel)"},{"issue":"2","key":"1515_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s13555-021-00662-1","volume":"12","author":"J Nowowiejska","year":"2022","unstructured":"Nowowiejska J, Baran A, Grabowska P, Lewoc M, Kaminski TW, Flisiak I. Assessment of life quality, stress and physical activity among patients with psoriasis. Dermatol Ther (Heidelb). 2022;12(2):395\u2013406. https:\/\/doi.org\/10.1007\/s13555-021-00662-1.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1515_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","volume":"37","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities. BioDrugs. 2023;37(1):35\u201355. https:\/\/doi.org\/10.1007\/s40259-022-00569-z.","journal-title":"BioDrugs"},{"issue":"5","key":"1515_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.4103\/ijd.ijd_611_23","volume":"68","author":"W Ding","year":"2023","unstructured":"Ding W, Yao M, Wang Y, et al. Patient needs in psoriasis treatment and their influencing factors: a nationwide multicentre cross-sectional study in China. Indian J Dermatol. 2023;68(5):587. https:\/\/doi.org\/10.4103\/ijd.ijd_611_23.","journal-title":"Indian J Dermatol"},{"issue":"4","key":"1515_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","volume":"22","author":"A Thatiparthi","year":"2021","unstructured":"Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ. Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol. 2021;22(4):425\u201342.","journal-title":"Am J Clin Dermatol"},{"key":"1515_CR8","unstructured":"Novartis. COSENTYX (secukinumab) injection, for subcutaneous or intravenous use: prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125504s066,761349s004lbl.pdf. Accessed 3 Aug 2024."},{"key":"1515_CR9","unstructured":"Novartis. Cosentyx 75\u00a0mg solution for injection in pre-filled syringe: summary of product characteristics. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf. Accessed 25 June 2025."},{"issue":"2","key":"1515_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/bjd\/ljac040","volume":"188","author":"RG Langley","year":"2023","unstructured":"Langley RG, Sofen H, Dei-Cas I, et al. Secukinumab long-term efficacy and safety in psoriasis through to year\u00a05 of treatment: results of a randomized extension of the phase\u00a0III ERASURE and FIXTURE trials. Br J Dermatol. 2023;188(2):198\u2013207.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1515_CR11","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.14878","volume":"32","author":"R Bissonnette","year":"2018","unstructured":"Bissonnette R, Luger T, Tha\u00e7i D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5\u00a0years of treatment (SCULPTURE extension study). J Eur Acad Dermatol Venereol. 2018;32(9):1507\u201314.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1515_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.03.033","volume":"83","author":"E Daud\u00e9n","year":"2020","unstructured":"Daud\u00e9n E, Carretero G, Rivera R, et al. Long-term safety of nine systemic medications for psoriasis: a cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) registry. J Am Acad Dermatol. 2020;83(1):139\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1515_CR13","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/jdv.18329","volume":"36","author":"M Augustin","year":"2022","unstructured":"Augustin M, Sator PG, von Kiedrowski R, et al. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study. J Eur Acad Dermatol Venereol. 2022;36(10):1796\u2013804.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1515_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2200868","volume":"34","author":"S Dastoli","year":"2023","unstructured":"Dastoli S, Passante M, Loconsole F, et al. Long-term efficacy and safety of secukinumab in real life: a 240\u00a0weeks multicenter study from Southern Italy. J Dermatolog Treat. 2023;34(1):2200868.","journal-title":"J Dermatolog Treat"},{"issue":"10275","key":"1515_CR15","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","volume":"397","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi K, Balato A, Enerback C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(21)00184-7.","journal-title":"Lancet"},{"key":"1515_CR16","unstructured":"Metaplan. Metaplan basic techniques: moderating group discussions using the Metaplan approach. 2021. https:\/\/www.metaplan.com\/wp-content\/uploads\/2021\/04\/Metaplan_Basiswissen_engl.pdf. Accessed 30 July 2024."},{"issue":"1","key":"1515_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/jdv.15920","volume":"34","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, Andersen YMF, Halling-Overgaard AS, et al. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. J Eur Acad Dermatol Venereol. 2020;34(1):39\u201346. https:\/\/doi.org\/10.1111\/jdv.15920.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1515_CR18","first-page":"34","volume":"22","author":"L Mastorino","year":"2024","unstructured":"Mastorino L, Dapavo P, Susca S, et al. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment. J Dtsch Dermatol Ges. 2024;22(1):34\u201342.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"1515_CR19","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/jdv.16180","volume":"34","author":"M Augustin","year":"2020","unstructured":"Augustin M, Jullien D, Martin A, Peralta C. Real-world evidence of secukinumab in psoriasis treatment \u2013 a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2020;34(6):1174\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1515_CR20","doi-asserted-by":"publisher","DOI":"10.33590\/emjallergyimmunol\/10301362","author":"S Batta","year":"2023","unstructured":"Batta S, Khan R, Zaayman M, Limmer A, Kivelevitch D, Menter A. IL-17 and -23 inhibitors for the treatment of psoriasis. EMJ Allergy Immunol. 2023. https:\/\/doi.org\/10.33590\/emjallergyimmunol\/10301362.","journal-title":"EMJ Allergy Immunol"},{"key":"1515_CR21","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.563","volume":"102","author":"AB Gottlieb","year":"2022","unstructured":"Gottlieb AB, Deodhar A, McInnes IB, et al. Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data. Acta Derm Venereol. 2022;102:adv00698.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1515_CR22","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40744-022-00434-z","volume":"9","author":"JF Merola","year":"2022","unstructured":"Merola JF, McInnes IB, Deodhar AA, et al. Effect of secukinumab on traditional cardiovascular risk factors and inflammatory biomarkers: post hoc analyses of pooled data across three indications. Rheumatol Ther. 2022;9(3):935\u201355.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"1515_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/14712598.2020.1708897","volume":"20","author":"M Galluzzo","year":"2020","unstructured":"Galluzzo M, D\u2019Adamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136\u00a0weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther. 2020;20(2):173\u201382.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"1515_CR24","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/jdv.18846","volume":"37","author":"L Iversen","year":"2023","unstructured":"Iversen L, Conrad C, Eidsmo L, et al. Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: week\u00a052 results from the STEPIn study. J Eur Acad Dermatol Venereol. 2023;37(5):1004\u201316.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1515_CR25","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jaad.2022.04.060","volume":"88","author":"J Kim","year":"2023","unstructured":"Kim J, Lee J, Hawkes JE, et al. Secukinumab improves mild-to-moderate psoriasis: a randomized, placebo-controlled exploratory clinical trial. J Am Acad Dermatol. 2023;88(2):428\u201330.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1515_CR26","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/09546634.2019.1671577","volume":"31","author":"A Chiricozzi","year":"2020","unstructured":"Chiricozzi A, Balato A, Conrad C, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatolog Treat. 2020;31(5):476\u201383. https:\/\/doi.org\/10.1080\/09546634.2019.1671577.","journal-title":"J Dermatolog Treat"},{"key":"1515_CR27","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.2147\/ccid.S416149","volume":"16","author":"F Russo","year":"2023","unstructured":"Russo F, Galluzzo M, Stingeni L, et al. Long-term drug survival and effectiveness of secukinumab in patients with moderate to severe chronic plaque psoriasis: 42-month results from the SUPREME 2.0 study. Clin Cosmet Investig Dermatol. 2023;16:3561\u201374. https:\/\/doi.org\/10.2147\/ccid.S416149.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"1515_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13006","volume":"32","author":"N Rompoti","year":"2019","unstructured":"Rompoti N, Katsimbri P, Kokkalis G, et al. Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: a 104-week clinical study. Dermatol Ther. 2019;32(5):e13006.","journal-title":"Dermatol Ther"},{"key":"1515_CR29","first-page":"75","volume":"8","author":"EJ Yang","year":"2018","unstructured":"Yang EJ, Beck KM, Liao W. Secukinumab in the treatment of psoriasis: patient selection and perspectives. Psoriasis (Auckl). 2018;8:75\u201382.","journal-title":"Psoriasis (Auckl)"},{"issue":"6","key":"1515_CR30","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s13555-020-00441-4","volume":"10","author":"M Honma","year":"2020","unstructured":"Honma M, Cai Z, Burge R, Zhu B, Yotsukura S, Torisu-Itakura H. Relationship between rapid skin clearance and quality of life benefit: post hoc analysis of Japanese patients with moderate-to-severe psoriasis treated with ixekizumab (UNCOVER-J). Dermatol Ther (Heidelb). 2020;10(6):1397\u2013404.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1515_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","volume":"3","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based Multinational Assessment of Psoriasis and Psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3(1):91\u2013102. https:\/\/doi.org\/10.1007\/s40744-016-0029-z.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"1515_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13075-019-1957-0","volume":"21","author":"E Kampylafka","year":"2019","unstructured":"Kampylafka E, Simon D, d\u2019Oliveira I, et al. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation\u2014data from the prospective IVEPSA study. Arthritis Res Ther. 2019;21(1):178. https:\/\/doi.org\/10.1186\/s13075-019-1957-0.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"1515_CR33","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/art.40778","volume":"71","author":"L Savage","year":"2019","unstructured":"Savage L, Goodfield M, Horton L, et al. Regression of peripheral subclinical enthesopathy in therapy-naive patients treated with ustekinumab for moderate-to-severe chronic plaque psoriasis: a fifty-two-week, prospective, open-label feasibility study. Arthritis Rheumatol. 2019;71(4):626\u201331.","journal-title":"Arthritis Rheumatol"},{"key":"1515_CR34","doi-asserted-by":"publisher","first-page":"740968","DOI":"10.3389\/fimmu.2021.740968","volume":"12","author":"P Liu","year":"2021","unstructured":"Liu P, Kuang Y, Ye L, et al. Predicting the risk of psoriatic arthritis in plaque psoriasis patients: development and assessment of a new predictive nomogram. Front Immunol. 2021;12:740968. https:\/\/doi.org\/10.3389\/fimmu.2021.740968.","journal-title":"Front Immunol"},{"issue":"1","key":"1515_CR35","doi-asserted-by":"publisher","first-page":"300060523122101","DOI":"10.1177\/03000605231221014","volume":"52","author":"WY Loo","year":"2024","unstructured":"Loo WY, Tee YC, Han WH, et al. Predictive factors of psoriatic arthritis in a diverse population with psoriasis. J Int Med Res. 2024;52(1):3000605231221014. https:\/\/doi.org\/10.1177\/03000605231221014.","journal-title":"J Int Med Res"},{"issue":"3","key":"1515_CR36","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/bjd.19262","volume":"184","author":"K Reich","year":"2021","unstructured":"Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. 2021;184(3):425\u201336.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1515_CR37","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard-2023-224148","volume":"82","author":"A Zabotti","year":"2023","unstructured":"Zabotti A, De Marco G, Gossec L, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023;82(9):1162\u201370.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1515_CR38","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.3390\/life12122050","volume":"12","author":"AC Nicolescu","year":"2022","unstructured":"Nicolescu AC, Ionescu MA, Constantin MM, et al. Psoriasis management challenges regarding difficult-to-treat areas: therapeutic decision and effectiveness. Life (Basel). 2022;12(12):2050. https:\/\/doi.org\/10.3390\/life12122050.","journal-title":"Life (Basel)"},{"issue":"4","key":"1515_CR39","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1515_CR40","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/14712598.2022.2029841","volume":"22","author":"M Galluzzo","year":"2022","unstructured":"Galluzzo M, Talamonti M, Atzori L, et al. Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study. Expert Opin Biol Ther. 2022;22(4):547\u201354. https:\/\/doi.org\/10.1080\/14712598.2022.2029841.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"1515_CR41","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/jdv.16124","volume":"34","author":"K Reich","year":"2020","unstructured":"Reich K, Warren RB, Coates LC, Di Comite G. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol. 2020;34(6):1161\u201373.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1515_CR42","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40257-016-0211-7","volume":"17","author":"P Gisondi","year":"2016","unstructured":"Gisondi P, Del Giglio M, Girolomoni G. Considerations for systemic treatment of psoriasis in obese patients. Am J Clin Dermatol. 2016;17(6):609\u201315.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"1515_CR43","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.3390\/medicina59112006","volume":"59","author":"A Czarnecka","year":"2023","unstructured":"Czarnecka A, Zab\u0142otna M, Purzycka-Bohdan D, Nowicki RJ, Szczerkowska-Dobosz A. An observational study of 147 psoriasis patients: overweightness and obesity as a significant clinical factors correlated with psoriasis. Medicina (Kaunas). 2023;59(11):2006. https:\/\/doi.org\/10.3390\/medicina59112006.","journal-title":"Medicina (Kaunas)"},{"issue":"12","key":"1515_CR44","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1038\/nutd.2012.26","volume":"2","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54.","journal-title":"Nutr Diabetes"},{"issue":"10","key":"1515_CR45","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","volume":"41","author":"F Pirro","year":"2021","unstructured":"Pirro F, Caldarola G, Chiricozzi A, et al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41(10):917\u201325.","journal-title":"Clin Drug Investig"},{"issue":"8","key":"1515_CR46","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/09546634.2019.1626973","volume":"31","author":"A Pinter","year":"2020","unstructured":"Pinter A, Gerdes S, Papavassilis C, Reinhardt M. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. J Dermatolog Treat. 2020;31(8):769\u201375. https:\/\/doi.org\/10.1080\/09546634.2019.1626973.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1515_CR47","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/jdv.16202","volume":"34","author":"N Rompoti","year":"2020","unstructured":"Rompoti N, Sidiropoulou P, Panagakis P, et al. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response. J Eur Acad Dermatol Venereol. 2020;34(6):1240\u20137. https:\/\/doi.org\/10.1111\/jdv.16202.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1515_CR48","doi-asserted-by":"publisher","first-page":"374","DOI":"10.25251\/skin.3.6.2","volume":"3","author":"R Vender","year":"2019","unstructured":"Vender R. Transitioning between biologics. SKIN J Cutan Med. 2019;3(6):374\u201380. https:\/\/doi.org\/10.25251\/skin.3.6.2.","journal-title":"SKIN J Cutan Med"},{"issue":"6","key":"1515_CR49","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/dth.12267","volume":"28","author":"F Kerdel","year":"2015","unstructured":"Kerdel F, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther. 2015;28(6):390\u2013403. https:\/\/doi.org\/10.1111\/dth.12267.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1515_CR50","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13599","volume":"33","author":"L Shi","year":"2020","unstructured":"Shi L, Lian N, Liu L, Chen M. Tapering and discontinuation of systemic medications in psoriasis patients with low disease activity. Dermatol Ther. 2020;33(4):e13599. https:\/\/doi.org\/10.1111\/dth.13599.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1515_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1590\/abd1806-4841.20164169","volume":"91","author":"J Machado-Pinto","year":"2016","unstructured":"Machado-Pinto J, dos Santos Diniz DM, Couto Bavoso N. Psoriasis: new comorbidities. An Bras Dermatol. 2016;91(1):8\u201314. https:\/\/doi.org\/10.1590\/abd1806-4841.20164169.","journal-title":"An Bras Dermatol"},{"issue":"1","key":"1515_CR52","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jamadermatol.2023.4846","volume":"160","author":"A Al-Janabi","year":"2024","unstructured":"Al-Janabi A, Alabas OA, Yiu ZZN, et al. Risk of paradoxical eczema in patients receiving biologics for psoriasis. JAMA Dermatol. 2024;160(1):71\u20139.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1515_CR53","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s12026-022-09356-y","volume":"71","author":"A Ruggiero","year":"2023","unstructured":"Ruggiero A, Megna M, Fabbrocini G, Ocampo-Garza SS. Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data. Immunol Res. 2023;71(3):328\u201355.","journal-title":"Immunol Res"},{"key":"1515_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1331217","volume":"15","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Eyerich K, Kuchroo VK, et al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024;15:1331217.","journal-title":"Front Immunol"},{"issue":"5","key":"1515_CR55","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","volume":"139","author":"E von Stebut","year":"2019","unstructured":"von Stebut E, Reich K, Tha\u00e7i D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52\u00a0weeks. J Invest Dermatol. 2019;139(5):1054\u201362.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1515_CR56","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40266-018-0520-z","volume":"35","author":"A K\u00f6rber","year":"2018","unstructured":"K\u00f6rber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase\u00a0III studies. Drugs Aging. 2018;35(2):135\u201344. https:\/\/doi.org\/10.1007\/s40266-018-0520-z.","journal-title":"Drugs Aging"},{"key":"1515_CR57","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2147\/ccid.S400520","volume":"16","author":"M Talamonti","year":"2023","unstructured":"Talamonti M, Russo F, Malara G, et al. Efficacy and safety of secukinumab in elderly patients with moderate to severe plaque-type psoriasis: post-hoc analysis of the SUPREME study. Clin Cosmet Investig Dermatol. 2023;16:847\u201352. https:\/\/doi.org\/10.2147\/ccid.S400520.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"Suppl 1","key":"1515_CR58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000501993","volume":"11","author":"A Gambardella","year":"2019","unstructured":"Gambardella A. Secukinumab in the treatment of plaque psoriasis in patients with malignancy. Case Rep Dermatol. 2019;11(Suppl 1):11\u20136.","journal-title":"Case Rep Dermatol"},{"issue":"6","key":"1515_CR59","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40261-022-01163-5","volume":"42","author":"M Megna","year":"2022","unstructured":"Megna M, Patruno C, Bongiorno MR, et al. Hepatitis virus reactivation in patients with psoriasis treated with secukinumab in a real-world setting of hepatitis\u00a0B or hepatitis\u00a0C infection. Clin Drug Investig. 2022;42(6):525\u201331. https:\/\/doi.org\/10.1007\/s40261-022-01163-5.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"1515_CR60","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2340\/00015555-2989","volume":"98","author":"HY Chiu","year":"2018","unstructured":"Chiu HY, Hui RC, Huang YH, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis\u00a0B or C: a multicentric prospective cohort study. Acta Derm Venereol. 2018;98(9):829\u201334. https:\/\/doi.org\/10.2340\/00015555-2989.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1515_CR61","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40257-024-00845-4","volume":"25","author":"T Torres","year":"2024","unstructured":"Torres T, Chiricozzi A, Puig L, et al. Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 inhibitors: a retrospective, multinational, multicentre study. Am J Clin Dermatol. 2024;25(2):333\u201342.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1515_CR62","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.abd.2023.12.004","volume":"99","author":"E Acer","year":"2024","unstructured":"Acer E, Erdogan HK, Agaoglu E, Basturk H, Bilgin M, Saracoglu ZN. Efficacy and safety of secukinumab in psoriasis: five-year real life experience. An Bras Dermatol. 2024;99(6):840\u20136.","journal-title":"An Bras Dermatol"},{"issue":"11","key":"1515_CR63","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1111\/jdv.19328","volume":"37","author":"K Kridin","year":"2023","unstructured":"Kridin K, Zirpel H, Mruwat N, Ludwig RJ, Thaci D. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - a population-based study. J Eur Acad Dermatol Venereol. 2023;37(11):2319\u201326. https:\/\/doi.org\/10.1111\/jdv.19328.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1515_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15610","volume":"35","author":"P Romita","year":"2022","unstructured":"Romita P, Foti C, Calianno G, Chiricozzi A. Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast. Dermatol Ther. 2022;35(8):e15610.","journal-title":"Dermatol Ther"},{"key":"1515_CR65","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.2147\/CCID.S395348","volume":"15","author":"J Gong","year":"2022","unstructured":"Gong J, Wu W, Qiu L, et al. Interleukin-17A inhibitor secukinumab treatment in HIV-positive psoriasis patient: a case report. Clin Cosmet Investig Dermatol. 2022;15:2949\u201356. https:\/\/doi.org\/10.2147\/CCID.S395348.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"1515_CR66","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000508781","volume":"12","author":"MCG Pangilinan","year":"2020","unstructured":"Pangilinan MCG, Sermswan P, Asawanonda P. Use of anti-IL-17 monoclonal antibodies in HIV patients with erythrodermic psoriasis. Case Rep Dermatol. 2020;12(2):132\u20137. https:\/\/doi.org\/10.1159\/000508781.","journal-title":"Case Rep Dermatol"},{"issue":"6","key":"1515_CR67","first-page":"646","volume":"17","author":"V Di Lernia","year":"2019","unstructured":"Di Lernia V, Casanova DM, Garlassi E. Secukinumab in an HIV-positive patient with psoriasis. J Dtsch Dermatol Ges. 2019;17(6):646\u20138.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1515_CR68","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.42081","volume":"105","author":"J Li","year":"2025","unstructured":"Li J, Xiang X, Wang Z, Miao C, Chen Y, Xu Z. Safety of interleukin inhibitors in psoriatic patients with latent tuberculosis infection without chemoprophylaxis: a systematic review. Acta Derm Venereol. 2025;105:adv42081.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1515_CR69","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.19039","volume":"183","author":"CH Smith","year":"2020","unstructured":"Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628\u201337.","journal-title":"Br J Dermatol"},{"key":"1515_CR70","doi-asserted-by":"publisher","first-page":"623759","DOI":"10.1155\/2014\/623759","volume":"2014","author":"B Yang","year":"2014","unstructured":"Yang B, Kang H, Fung A, Zhao H, Wang T, Ma D. The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm. 2014;2014:623759. https:\/\/doi.org\/10.1155\/2014\/623759.","journal-title":"Mediators Inflamm"},{"issue":"2","key":"1515_CR71","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/jdv.19520","volume":"38","author":"K Kridin","year":"2024","unstructured":"Kridin K, Abdelghaffar M, Mruwat N, Ludwig RJ, Tha\u00e7i D. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?\u2014insights from an international population-based study. J Eur Acad Dermatol Venereol. 2024;38(2):315\u201324.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1515_CR72","doi-asserted-by":"publisher","first-page":"21094","DOI":"10.1038\/s41598-020-78204-6","volume":"10","author":"MH Kaaij","year":"2020","unstructured":"Kaaij MH, Helder B, van Mens LJJ, van de Sande MGH, Baeten DLP, Tas SW. Anti-IL-17A treatment reduces serum inflammatory, angiogenic and tissue remodeling biomarkers accompanied by less synovial high endothelial venules in peripheral spondyloarthritis. Sci Rep. 2020;10(1):21094. https:\/\/doi.org\/10.1038\/s41598-020-78204-6.","journal-title":"Sci Rep"},{"issue":"20","key":"1515_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206216","volume":"13","author":"T Ocak","year":"2024","unstructured":"Ocak T, Ya\u011f\u0131z B, Ocak B, et al. Secukinumab may be an effective treatment option for axial spondyloarthritis and psoriatic arthritis patients with a history of malignancy: multicenter real-life experience from Turkey. J Clin Med. 2024;13(20):6216.","journal-title":"J Clin Med"},{"issue":"7","key":"1515_CR74","first-page":"2878","volume":"28","author":"UG Massafra","year":"2024","unstructured":"Massafra UG, Giovannangeli F, Migliore A. Psoriatic arthropathy in patients with previous neoplasia: a case series of four patients treated with secukinumab and literature review. Eur Rev Med Pharmacol Sci. 2024;28(7):2878\u201393.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"11","key":"1515_CR75","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00296-024-05571-y","volume":"44","author":"N Farina","year":"2024","unstructured":"Farina N, Tomelleri A, Boffini N, et al. Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease. Rheumatol Int. 2024;44(11):2431\u20134. https:\/\/doi.org\/10.1007\/s00296-024-05571-y.","journal-title":"Rheumatol Int"},{"issue":"9","key":"1515_CR76","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3390\/life11090919","volume":"11","author":"\u00c9A Piros","year":"2021","unstructured":"Piros \u00c9A, Szab\u00f3 \u00c1, Rencz F, et al. Impact of interleukin-17 inhibitor therapy on arterial intima-media thickness among severe psoriatic patients. Life (Basel). 2021;11(9):919. https:\/\/doi.org\/10.3390\/life11090919.","journal-title":"Life (Basel)"},{"issue":"4","key":"1515_CR77","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/bjd.14964","volume":"176","author":"W Rungapiromnan","year":"2017","unstructured":"Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017;176(4):890\u2013901.","journal-title":"Br J Dermatol"},{"key":"1515_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1203372","volume":"14","author":"R Queiro","year":"2023","unstructured":"Queiro R, Aurrecoechea E, Alonso Castro S, Villa Blanco I, Brandy-Garcia A, Linge R. Interleukin-17-targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile. Front Immunol. 2023;14:1203372.","journal-title":"Front Immunol"},{"issue":"5","key":"1515_CR79","volume":"16","author":"R Ni","year":"2024","unstructured":"Ni R, Zheng J, Varghese J, Kumar B. The impact of interleukin-17 inhibitors on major adverse cardiovascular events in psoriasis or psoriatic arthritis patients naive to biologic agents: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2024;16(5):e60980.","journal-title":"Cureus"},{"issue":"4","key":"1515_CR80","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/cvr\/cvz009","volume":"115","author":"YA Elnabawi","year":"2019","unstructured":"Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115(4):721\u20138.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"1515_CR81","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s13555-022-00867-y","volume":"13","author":"HT Nguyen","year":"2023","unstructured":"Nguyen HT, Pham NTU, Tran TNA, Pham NN, Bui YT, Vu TTP. Long-term effectiveness and drug survival of secukinumab in Vietnamese patients with psoriasis: results from a retrospective ENHANCE study. Dermatol Ther (Heidelb). 2023;13(2):465\u201376. https:\/\/doi.org\/10.1007\/s13555-022-00867-y.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1515_CR82","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3945\/ajcn.2008.26427","volume":"88","author":"P Gisondi","year":"2008","unstructured":"Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr. 2008;88(5):1242\u20137.","journal-title":"Am J Clin Nutr"},{"key":"1515_CR83","first-page":"189","volume":"12","author":"S Yeroushalmi","year":"2022","unstructured":"Yeroushalmi S, Hakimi M, Chung M, Bartholomew E, Bhutani T, Liao W. Psoriasis and exercise: a review. Psoriasis (Auckl). 2022;12:189\u201397.","journal-title":"Psoriasis (Auckl)"},{"issue":"4","key":"1515_CR84","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/nu15040840","volume":"15","author":"E Duchnik","year":"2023","unstructured":"Duchnik E, Kruk J, Tuchowska A, Marchlewicz M. The impact of diet and physical activity on psoriasis: a narrative review of the current evidence. Nutrients. 2023;15(4):840. https:\/\/doi.org\/10.3390\/nu15040840.","journal-title":"Nutrients"},{"key":"1515_CR85","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/ptt.S323281","volume":"14","author":"L Potestio","year":"2024","unstructured":"Potestio L, Lauletta G, Tommasino N, et al. Risk factors for psoriasis flares: a narrative review. Psoriasis (Auckl). 2024;14:39\u201350. https:\/\/doi.org\/10.2147\/ptt.S323281.","journal-title":"Psoriasis (Auckl)"},{"key":"1515_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01951","volume":"11","author":"A Vaisman-Mentesh","year":"2020","unstructured":"Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol. 2020;11:1951.","journal-title":"Front Immunol"},{"issue":"1","key":"1515_CR87","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13555-018-0220-y","volume":"8","author":"S Spindeldreher","year":"2018","unstructured":"Spindeldreher S, Maill\u00e8re B, Correia E, et al. Secukinumab demonstrates significantly lower immunogenicity potential compared to ixekizumab. Dermatol Ther (Heidelb). 2018;8(1):57\u201368. https:\/\/doi.org\/10.1007\/s13555-018-0220-y.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"1515_CR88","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/BOR.0000000000001018","volume":"36","author":"EK Pender","year":"2024","unstructured":"Pender EK, Kirby B. An update on topical therapies for psoriasis. Curr Opin Rheumatol. 2024;36(4):289\u201394.","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"1515_CR89","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjd.20971","volume":"186","author":"M Augustin","year":"2022","unstructured":"Augustin M, Reich K, Yamauchi P, et al. Secukinumab dosing every 2\u00a0weeks demonstrated superior efficacy compared with dosing every 4\u00a0weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022;186(6):942\u201354.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1515_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061506","volume":"11","author":"E Piragine","year":"2022","unstructured":"Piragine E, Petri D, Martelli A, et al. Adherence and persistence to biological drugs for psoriasis: systematic review with meta-analysis. J Clin Med. 2022;11(6):1506.","journal-title":"J Clin Med"},{"key":"1515_CR91","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.2147\/ppa.S326498","volume":"15","author":"G Argenziano","year":"2021","unstructured":"Argenziano G, Amerio P, Aragone MG, et al. Assessing the beneficial impact of a patient support program in secukinumab-treated patients with psoriasis in Italy. Patient Prefer Adherence. 2021;15:2551\u201362. https:\/\/doi.org\/10.2147\/ppa.S326498.","journal-title":"Patient Prefer Adherence"},{"issue":"10","key":"1515_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102801","volume":"11","author":"F Prignano","year":"2022","unstructured":"Prignano F, Brunasso AMG, Fabbrocini G, et al. Sharing patient and clinician experiences of moderate-to-severe psoriasis: a nationwide Italian survey and expert opinion to explore barriers impacting upon patient wellbeing. J Clin Med. 2022;11(10):2801.","journal-title":"J Clin Med"},{"key":"1515_CR93","first-page":"25","volume":"12","author":"B Blackstone","year":"2022","unstructured":"Blackstone B, Patel R, Bewley A. Assessing and improving psychological well-being in psoriasis: considerations for the clinician. Psoriasis (Auckl). 2022;12:25\u201333.","journal-title":"Psoriasis (Auckl)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01515-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01515-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01515-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T18:02:49Z","timestamp":1761242569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01515-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":93,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1515"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01515-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anna Balato has served as consultant and\/or has received fees from: AbbVie, Almirall, Amgen, BMS, Boehringer Ingelheim, Eli Lilly, LEO Pharma, Janssen, Sanofi, and UCB. Anna Campanati has served as a speaker or board member for AbbVie, Almirall, Galderma, Celgene, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, and UCB; and is a current Editorial Board member for\n                      Dermatology and Therapy.\n                      Antonio Costanzo has served as a speaker or board member for AbbVie, Amgen, Galderma, Celgene, LEO Pharma, Eli Lilly, Boehringer Ingelheim, Novartis, Pfizer, and UCB. Paolo Gisondi is a current Editorial Board member for\n                      Dermatology and Therapy.\n                      Martina Burlando, Andrea Chiricozzi, Piergiorgio Malagoli, and Giuseppe Micali declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies (with human participants or animals) performed by any of the authors. Ethical approval was not required. All dermatologists signed a contract when they agreed to participate in the Psoriasis Working Group; the contract outlined the objectives of the advisory boards and stated that the voting results would be published. Dermatologists\u2019 data were protected by electronic storage with advanced security technologies and periodic backups to protect data integrity and confidentiality.The study sponsor (Novartis) selected the advisory board participants based on their clinical experience in managing patients with psoriasis but had no subsequent input into the project.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}